Navigation Links
Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy

Exam, or MMSE), overall clinical function (the Clinician's Interview-Based Impression of Change with a caregiver interview, or CIBC-plus), activities of daily living (the Alzheimer's Disease Cooperative Study Group-Activities of Daily Living, or ADCS-ADL), and behavioral problems (the Neuropsychiatric Inventory, or NPI). The study was conducted at multiple sites in Russia.

Dimebon Trial Six-Month Results

Medivation previously announced six-month results, showing that Dimebon- treated patients demonstrated significant improvement on the primary endpoint of ADAS-cog (p<0.0001) and the key secondary endpoint of CIBIC-plus (p<0.0001) compared with patients receiving placebo. Dimebon-treated patients also significantly outperformed the placebo-treated patients (p<0.01) on the three additional secondary endpoints: the ADCS-ADL, the NPI and the MMSE.

Teleconference/Webcast Details

Medivation will host a teleconference at 8:30 a.m. Eastern time today to discuss the data. To participate in the live call by telephone, please dial 800-565-5442 from the U.S. or 913-312-1298 internationally. A telephone replay will be available for seven days following the conclusion of the call by dialing 888-203-1112 from the U.S. or 719-457-0820 for international callers and entering passcode 4782383. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Dimebon

Dimebon, the Company's lead product candidate, is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Based on the clinical and preclinical data generated to date, Medivation believes that Dimebon operates
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
2. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
3. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimers Disease Conference
5. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
6. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
7. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
8. EPIX Pharmaceuticals Announces Statistically Significant Results in Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate
9. Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of Telcyta as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer
10. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
11. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
Post Your Comments:
(Date:5/17/2013)... , May 17, 2013  Atossa Genetics, Inc. (NASDAQ: ... Kyle Guse , Chief Financial Officer & ... MicroCap Conference on Thursday, May 30, 2013, in ... The Company,s presentation is scheduled to begin ... live webcast. To access the webcast, go to www.atossagenetics.com ...
(Date:5/17/2013)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( http://www.oramed.com ... today that the United States Food and Drug Administration ... for ORMD-0801, its oral insulin capsule. "We ... proceed," stated Nadav Kidron , CEO ... for Oramed and we look forward to continuing to ...
(Date:5/17/2013)... May 17, 2013  Boston Scientific Corporation (NYSE: ... annual EuroPCR Scientific Program May 21-24 in ... present a particularly rich and diversified set of data ... , M.D., global chief medical officer, Boston Scientific.  ... presented, including the NG PROMUS trial, which evaluated our ...
Breaking Medicine Technology:Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8
... the many new features of Monaco® 3.0, Dynamic Conformal Arc ... highly conformal stereotactic plans by using the multi-leaf collimator (MLC) ... rotates around the patient. DCA recently received 510(k) clearance for ... "DCA can be used to render more conformal plans by ...
... Mass., July 18, 2011 Endologix, Inc. (Nasdaq: ... treatments for aortic disorders, and LeMaitre Vascular, Inc. (Nasdaq: ... and implants, announced today that the companies have entered ... of Endologix,s aortic endovascular products in Europe.   ...
Cached Medicine Technology:New Release of Elekta's Monaco Treatment Planning System Prepares Software for Stereotactic Radiation Therapy 2Endologix and LeMaitre Vascular Enter Early Termination Agreement for European Distribution Rights of Endologix Products 2Endologix and LeMaitre Vascular Enter Early Termination Agreement for European Distribution Rights of Endologix Products 3Endologix and LeMaitre Vascular Enter Early Termination Agreement for European Distribution Rights of Endologix Products 4
(Date:5/19/2013)... 2013 Omaha, Nebraska is a city of ... with one of the lowest unemployment rates in the country. ... Best Places for Business and Careers and it consistently scores ... is centrally located in the nation and is a strong ... The producers of Editions TV are pleased to ...
(Date:5/19/2013)... Today, Zane Benefits, Inc. published ... insurance . Zane Benefits, which provides comprehensive and ... is the leader in health care reform, ... . , According to Zane Benefits’ website, many ... the value of small business health insurance for ...
(Date:5/19/2013)... May 19, 2013 The report “Feed ... Trends & Forecasts up to 2017” published by MarketsandMarkets, ... with analysis and forecasting of the global volume and ... the driving and restraining factors for the global market ... and challenges. The market is segmented and revenue is ...
(Date:5/19/2013)... Dr. Keith Chertok now provides gum disease patients with a ... the chance of a healthier smile. Laser gum surgery ... only removes diseased gum tissue in patients, but it also ... dental implants. , LANAP uses a laser to successfully ... stimulate the healthy tissue as well as encourage new bone ...
(Date:5/19/2013)... Exciting new Skin Brushes are available from ... practice known through the ages but is a lost ... brushing, has so many benefits for our health and ... love that circulation and lymphatic systems get a boost ... is supported through Skin Brushing." , Why is Skin ...
Breaking Medicine News(10 mins):Health News:Editions TV Announces May Air Dates for Omaha, Nebraska 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:Exciting New Skin Brushes at Sublime Beauty® Bring Health and Beauty Benefits; Celebrities and Models Know the Secret 2
... currently used to diagnose and guide treatment of ovarian cancer ... die from the disease or improve their quality of life, ... of the Agency for Healthcare Research and Quality, the Centers ... Control, and CDC’s National Office of Public Health Genomics. ...
... cuff injury in rats has revealed that exposure to ... rotator cuff repair could follow surgery in human patients. ... Washington University School of Medicine in St. Louis. ... from cardiovascular disease to lung disorders. Many of us ...
... possible factors that could probably play a significant role ... worldwide for years together, // has homed on to ... triggering off the development of autism in children . ... the communication skills and social interactions of an individual. ...
... the risk of deterioration after stroke, according to ... participated in after-stroke rehabilitative therapy proved better able ... to maintain these abilities, compared to patients who ... ,"The most important finding is that ...
... therapy reduces the severity of obsessive compulsive disorder in ... form of treatment helps relieve the overall distress // ... in young people’s lives. ,Further, the evidence indicates ... effective in treating pediatric OCD, say lead researcher Richard ...
... but still regularly indulging in french fries — don't count ... down, obese and overweight people need to watch what they ... weight-loss trials dating back to 1985. ,"Exercise by ... for an individual, you really need to combine exercise with ...
Cached Medicine News:Health News:Gene Tests to Identify Ovarian Cancer Have Little Clinical Value 2Health News:Gene Tests to Identify Ovarian Cancer Have Little Clinical Value 3Health News:Yet Another Reason not to Smoke 2Health News:Yet Another Reason not to Smoke 3Health News:Occupational Therapy Improves Independence in Stroke Survivors 2Health News:Occupational Therapy Improves Independence in Stroke Survivors 3Health News:Cognitive Behavioral Therapy Helps Children with Obsessive Compulsive Disorder 2Health News:Cognitive Behavioral Therapy Helps Children with Obsessive Compulsive Disorder 3Health News:Sit-Ups and Sundaes Don't Mix: Diet With Exercise Works Best 2Health News:Sit-Ups and Sundaes Don't Mix: Diet With Exercise Works Best 3
VerdaSee Dock Door Portal ID solutions provide high performance tracking of assets that enter or leave healthcare facilities through dock doors....
VerdaSee Portal ID is a family of solutions that provide automated tracking and tracing of assets as they enter or leave designated areas within a healthcare facility....
The AeroScout Exciter extends the AeroScout system to provide robust and sophisticated RFID detection capabilities....
... Exit Alerting System, instantly help ... and assets (e.g. medical equipment), ... throughout your facility. With this ... quickly ensured the cost savings, ...
Medicine Products: